Prescribed by a hepatologist or infectious disease specialist for adult patients with: 🔹 Chronic Hepatitis C infection (genotypes 1, 2, 3, 4). 🔹 Both treatment-naive patients and those who have failed prior therapy. 🔹 Suitable for patients with compensated cirrhosis.

Dosage and administration

Sales Unit: Plastic bottle in a carton box containing 28 tablets. Strength: 60 mg Daclatasvir / 400 mg Sofosbuvir per tablet. ⚠️ APPLICATION INSTRUCTIONS: Dosage: Take 1 tablet daily. Administration: Swallow the tablet whole; do not chew, crush, or break it. Can be taken with or without food. Consistency is key—take it at the same time every day. Treatment Duration: The standard course is 12 weeks (3 packs). In some clinical cases, a 24-week course may be required as per medical advice. ✋ Warning: Do not skip doses to maintain the required concentration of the drug in your system.

⛔ Drug Interactions: Do not use with amiodarone (due to risk of severe bradycardia), rifampin, St. John’s wort, or certain anticonvulsants. Pregnancy and breastfeeding. Children and adolescents under 18 years of age. Hypersensitivity to any of the components.

Most patients experience very few side effects. Potential mild reactions include: 💤 Fatigue or asthenia. 🧠 Headache or dizziness. 🤢 Mild nausea.

Hepcinat Plus — Daclatasvir 60 mg + 400 mg, 28 product-page.units_short, Natco

100% original product

Active ingredient

Daclatasvir Sofosbuvir

Manufacturer

Natco

Dosage 60 mg + 400 mg

Dosage form Tablets

Tablets per pack 28

Hepcinat Plus Tablets — Daclatasvir + Sofosbuvir 60+400 mg (28 Tabs)

Name: Hepcinat Plus
Brand: Natco
SKU: PROD-244
Price: 3910 UAH
Availability: InStock

3910₴ ~~4562₴~~ -14%

Hepcinat Plus is an advanced combined direct-acting antiviral (DAA) medication for the treatment of chronic Hepatitis C. Each tablet contains a potent combination of Daclatsvir (60 mg) and Sofosbuvir (400 mg). This dual-action formula targets the virus by inhibiting both NS5B and NS5A enzymes, which completely halts viral replication and clears the infection from the body.

Manufacturer: Natco Pharma Ltd. (India). 🇮🇳 Manufactured under license according to international quality standards, Hepcinat Plus provides a cure rate (Sustained Virologic Response) of 95–99% across a wide range of patient profiles, including those who have failed previous interferon-based treatments.

Key Features:

✅ Pangenotypic Potential: Highly effective against major Hepatitis C genotypes (1, 2, 3, and 4).
✅ 2-in-1 Convenience: Eliminates the need for multiple separate pills, combining the full daily therapeutic dose into one Hepcinat Plus tablet.
✅ High Tolerability: Significantly fewer side effects compared to older treatment regimens.

Prescribed by a hepatologist or infectious disease specialist for adult patients with:

🔹 Chronic Hepatitis C infection (genotypes 1, 2, 3, 4).
🔹 Both treatment-naive patients and those who have failed prior therapy.
🔹 Suitable for patients with compensated cirrhosis.

Sales Unit: Plastic bottle in a carton box containing 28 tablets. Strength: 60 mg Daclatasvir / 400 mg Sofosbuvir per tablet.

⚠️ APPLICATION INSTRUCTIONS:

Dosage: Take 1 tablet daily.
Administration: Swallow the tablet whole; do not chew, crush, or break it. Can be taken with or without food. Consistency is key—take it at the same time every day.
Treatment Duration: The standard course is 12 weeks (3 packs). In some clinical cases, a 24-week course may be required as per medical advice.
✋ Warning: Do not skip doses to maintain the required concentration of the drug in your system.

⛔ Drug Interactions: Do not use with amiodarone (due to risk of severe bradycardia), rifampin, St. John’s wort, or certain anticonvulsants.
Pregnancy and breastfeeding.
Children and adolescents under 18 years of age.
Hypersensitivity to any of the components.